254 related articles for article (PubMed ID: 29687281)
1. Prognostic value of Ki-67 index in adult medulloblastoma after accounting for molecular subgroup: a retrospective clinical and molecular analysis.
Zhao F; Zhang J; Li P; Zhou Q; Zhang S; Zhao C; Wang B; Yang Z; Li C; Liu P
J Neurooncol; 2018 Sep; 139(2):333-340. PubMed ID: 29687281
[TBL] [Abstract][Full Text] [Related]
2. Molecular subgroups of adult medulloblastoma: a long-term single-institution study.
Zhao F; Ohgaki H; Xu L; Giangaspero F; Li C; Li P; Yang Z; Wang B; Wang X; Wang Z; Ai L; Zhang J; Luo L; Liu P
Neuro Oncol; 2016 Jul; 18(7):982-90. PubMed ID: 27106407
[TBL] [Abstract][Full Text] [Related]
3. Prognostic effect of whole chromosomal aberration signatures in standard-risk, non-WNT/non-SHH medulloblastoma: a retrospective, molecular analysis of the HIT-SIOP PNET 4 trial.
Goschzik T; Schwalbe EC; Hicks D; Smith A; Zur Muehlen A; Figarella-Branger D; Doz F; Rutkowski S; Lannering B; Pietsch T; Clifford SC
Lancet Oncol; 2018 Dec; 19(12):1602-1616. PubMed ID: 30392813
[TBL] [Abstract][Full Text] [Related]
4. Medulloblastoma in China: clinicopathologic analyses of SHH, WNT, and non-SHH/WNT molecular subgroups reveal different therapeutic responses to adjuvant chemotherapy.
Zhang ZY; Xu J; Ren Y; Li KK; Ng HK; Mao Y; Zhong P; Yao Y; Zhou LF
PLoS One; 2014; 9(6):e99490. PubMed ID: 24932704
[TBL] [Abstract][Full Text] [Related]
5. The clinical treatment and outcome of cerebellopontine angle medulloblastoma: a retrospective study of 15 cases.
Wu T; Qu PR; Zhang S; Li SW; Zhang J; Wang B; Liu P; Li CD; Zhao F
Sci Rep; 2020 Jun; 10(1):9769. PubMed ID: 32555264
[TBL] [Abstract][Full Text] [Related]
6. Medulloblastoma with transitional features between Group 3 and Group 4 is associated with good prognosis.
Łastowska M; Trubicka J; Niemira M; Paczkowska-Abdulsalam M; Karkucińska-Więckowska A; Kaleta M; Drogosiewicz M; Perek-Polnik M; Krętowski A; Cukrowska B; Grajkowska W; Dembowska-Bagińska B; Matyja E
J Neurooncol; 2018 Jun; 138(2):231-240. PubMed ID: 29427151
[TBL] [Abstract][Full Text] [Related]
7. Approach to molecular subgrouping of medulloblastomas: Comparison of NanoString nCounter assay versus combination of immunohistochemistry and fluorescence in-situ hybridization in resource constrained centres.
Kaur K; Jha P; Pathak P; Suri V; Sharma MC; Garg A; Suri A; Sarkar C
J Neurooncol; 2019 Jul; 143(3):393-403. PubMed ID: 31104222
[TBL] [Abstract][Full Text] [Related]
8. [Analysis of pathologic characteristics and prognosis in different subtypes of adult medulloblastoma].
Zhao F; Zhang J; Wang X; Wang Z; Wang Y; Qu P; Luo L; Liu P
Zhonghua Bing Li Xue Za Zhi; 2014 Mar; 43(3):169-72. PubMed ID: 24842015
[TBL] [Abstract][Full Text] [Related]
9. Histologic Correlates of Molecular Group 4 Pediatric Medulloblastoma: A Retrospective Canadian Review.
Triscott J; Yip S; Johnston D; Michaud J; Rassekh SR; Hukin J; Dunn S; Dunham C
Pediatr Dev Pathol; 2021; 24(4):309-317. PubMed ID: 33749384
[TBL] [Abstract][Full Text] [Related]
10. Proteomic profiling of medulloblastoma reveals novel proteins differentially expressed within each molecular subgroup.
Narayan V; Jaiswal J; Sugur H; Sd S; Rao S; Chatterjee A; Gowda H; A A; Somanna S; Santosh V
Clin Neurol Neurosurg; 2020 Sep; 196():106028. PubMed ID: 32580068
[TBL] [Abstract][Full Text] [Related]
11. Immunohistochemical expression of markers Ki-67, neun, synaptophysin, p53 and HER2 in medulloblastoma and its correlation with clinicopathological parameters.
Meurer RT; Martins DT; Hilbig A; Ribeiro Mde C; Roehe AV; Barbosa-Coutinho LM; Fernandes Mda C
Arq Neuropsiquiatr; 2008 Jun; 66(2B):385-90. PubMed ID: 18641877
[TBL] [Abstract][Full Text] [Related]
12. Clinicopathological characteristics, molecular subgrouping, and expression of miR-379/miR-656 cluster (C14MC) in adult medulloblastomas.
Kaur K; Kakkar A; Kumar A; Purkait S; Mallick S; Suri V; Sharma MC; Julka PK; Gupta D; Suri A; Sarkar C
J Neurooncol; 2016 Dec; 130(3):423-430. PubMed ID: 27576698
[TBL] [Abstract][Full Text] [Related]
13. Subgroup-specific prognostic signaling and metabolic pathways in pediatric medulloblastoma.
Park AK; Lee JY; Cheong H; Ramaswamy V; Park SH; Kool M; Phi JH; Choi SA; Cavalli F; Taylor MD; Kim SK
BMC Cancer; 2019 Jun; 19(1):571. PubMed ID: 31185958
[TBL] [Abstract][Full Text] [Related]
14. DNA methylation profiling is a method of choice for molecular verification of pediatric WNT-activated medulloblastomas.
Korshunov A; Sahm F; Zheludkova O; Golanov A; Stichel D; Schrimpf D; Ryzhova M; Potapov A; Habel A; Meyer J; Lichter P; Jones DTW; von Deimling A; Pfister SM; Kool M
Neuro Oncol; 2019 Feb; 21(2):214-221. PubMed ID: 30252101
[TBL] [Abstract][Full Text] [Related]
15. A clinicobiological model predicting survival in medulloblastoma.
Ray A; Ho M; Ma J; Parkes RK; Mainprize TG; Ueda S; McLaughlin J; Bouffet E; Rutka JT; Hawkins CE
Clin Cancer Res; 2004 Nov; 10(22):7613-20. PubMed ID: 15569993
[TBL] [Abstract][Full Text] [Related]
16. Subgroup and subtype-specific outcomes in adult medulloblastoma.
Coltin H; Sundaresan L; Smith KS; Skowron P; Massimi L; Eberhart CG; Schreck KC; Gupta N; Weiss WA; Tirapelli D; Carlotti C; Li KKW; Ryzhova M; Golanov A; Zheludkova O; Absalyamova O; Okonechnikov K; Stichel D; von Deimling A; Giannini C; Raskin S; Van Meir EG; Chan JA; Fults D; Chambless LB; Kim SK; Vasiljevic A; Faure-Conter C; Vibhakar R; Jung S; Leary S; Mora J; McLendon RE; Pollack IF; Hauser P; Grajkowska WA; Rubin JB; van Veelen MC; French PJ; Kros JM; Liau LM; Pfister SM; Kool M; Kijima N; Taylor MD; Packer RJ; Northcott PA; Korshunov A; Ramaswamy V
Acta Neuropathol; 2021 Nov; 142(5):859-871. PubMed ID: 34409497
[TBL] [Abstract][Full Text] [Related]
17. Histological variants of medulloblastoma are the most powerful clinical prognostic indicators.
Massimino M; Antonelli M; Gandola L; Miceli R; Pollo B; Biassoni V; Schiavello E; Buttarelli FR; Spreafico F; Collini P; Giangaspero F
Pediatr Blood Cancer; 2013 Feb; 60(2):210-6. PubMed ID: 22693015
[TBL] [Abstract][Full Text] [Related]
18. DJ-1 is activated in medulloblastoma and is associated with cell proliferation and differentiation.
Lin JP; Pan BC; Li B; Li Y; Tian XY; Li Z
World J Surg Oncol; 2014 Dec; 12():373. PubMed ID: 25475127
[TBL] [Abstract][Full Text] [Related]
19. Transcriptome analysis stratifies second-generation non-WNT/non-SHH medulloblastoma subgroups into clinically tractable subtypes.
Korshunov A; Okonechnikov K; Schrimpf D; Tonn S; Mynarek M; Koster J; Sievers P; Milde T; Sahm F; Jones DTW; von Deimling A; Pfister SM; Kool M
Acta Neuropathol; 2023 Jun; 145(6):829-842. PubMed ID: 37093271
[TBL] [Abstract][Full Text] [Related]
20. M1 macrophage recruitment correlates with worse outcome in SHH Medulloblastomas.
Lee C; Lee J; Choi SA; Kim SK; Wang KC; Park SH; Kim SH; Lee JY; Phi JH
BMC Cancer; 2018 May; 18(1):535. PubMed ID: 29739450
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
